




The relative strengths and weaknesses of Cubist Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cubist Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Cubist Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 98% points.

The company's Economic Capital Ratio, given in the ranking table, is 245%, being 11% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	1,043,274
Cost of Goods Sold	172,864
Intangible Assets	297,113
Liabilities, Current	252,385
Liabilities, Non-Current	30,039
Other Assets	378,643
Other Compr. Net Income	0
Other Expenses	172,582
Other Liabilities	805,174
Other Net Income	-27,742
Other Revenues	753,972
Property and Equipment	168,425
Research and Development	184,533
Selling, General and Administrative Expense	163,228

Output Variable	Value in 1000 USD
Assets	1,887,455
Liabilities	1,087,598
Expenses	693,207
Revenues	753,972
Stockholders Equity	799,857
Net Income	33,023
Comprehensive Net Income	33,023
BaseVar	2,224,987
ECR before LimitedLiability	119%
Economic Capital Ratio	245%